{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:40:16Z","timestamp":1790840416683,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.bcp.2024.116397","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T15:49:42Z","timestamp":1719503382000},"page":"116397","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments"],"prefix":"10.1016","volume":"226","author":[{"given":"Claudia","family":"Fumarola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"La Monica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Bonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Zoppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Alfieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maricla","family":"Galetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Gnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Campanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cavazzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Mazzaschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico Maria","family":"Silini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Giorgio","family":"Petronini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2024.116397_b0005","doi-asserted-by":"crossref","unstructured":"Ouzaid I. Kidney Cancer. Prog en Urol - FMC. 2017:F43-F45. doi:10.1016\/j.fpurol.2017.04.004.","DOI":"10.1016\/j.fpurol.2017.04.004"},{"issue":"4","key":"10.1016\/j.bcp.2024.116397_b0010","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/14737140.2021.1861941","article-title":"The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinoma","volume":"21","author":"Bersanelli","year":"2021","journal-title":"Expert. Rev. Anticancer Ther."},{"issue":"10","key":"10.1016\/j.bcp.2024.116397_b0015","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1158\/2159-8290.CD-19-0499","article-title":"Tumor microenvironment dynamics in clear-cell renal cell carcinoma","volume":"9","author":"Vuong","year":"2019","journal-title":"Cancer Discov."},{"issue":"13","key":"10.1016\/j.bcp.2024.116397_b0020","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1158\/1078-0432.CCR-14-2926","article-title":"Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer","volume":"21","author":"Giraldo","year":"2015","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"issue":"13","key":"10.1016\/j.bcp.2024.116397_b0025","first-page":"5132","article-title":"Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity","volume":"61","author":"Nakano","year":"2001","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.bcp.2024.116397_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12071945","article-title":"The value of pd-l1 expression as predictive biomarker in metastatic renal cell carcinoma patients: A meta-analysis of randomized clinical trials","volume":"12","author":"Carretero-gonz\u00e1lez","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bcp.2024.116397_b0035","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12943-018-0800-6","article-title":"Targeting tumour microenvironment by tyrosine kinase inhibitor","volume":"17","author":"Tan","year":"2018","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.bcp.2024.116397_b0040","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.eururo.2017.02.010","article-title":"CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma","volume":"72","author":"Escudier","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bcp.2024.116397_b0045","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.563249","article-title":"Simultaneous combination of the CDK4\/6 inhibitor palbociclib with regorafenib induces enhanced anti-tumor effects in hepatocarcinoma cell lines","volume":"10","author":"Digiacomo","year":"2020","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2024.116397_b0050","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13046-018-0741-3","article-title":"The anti-tumor efficacy of CDK4\/6 inhibition is enhanced by the combination with PI3K\/AKT\/mTOR inhibitors through impairment of glucose metabolism in TNBC cells","volume":"37","author":"Cretella","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bcp.2024.116397_b0055","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030666","article-title":"Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer","volume":"12","author":"Cavazzoni","year":"2020","journal-title":"Cancers (Basel)."},{"issue":"1","key":"10.1016\/j.bcp.2024.116397_b0060","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13046-017-0653-7","article-title":"Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines","volume":"36","author":"La Monica","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2024.116397_b0065","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep."},{"issue":"12","key":"10.1016\/j.bcp.2024.116397_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjopen-2019-030522","article-title":"A prospective, open-label, interventional study protocol to evaluate treatment efficacy of nivolumab based on serum-soluble PD-L1 concentration for patients with metastatic and unresectable renal cell carcinoma","volume":"9","author":"Bando","year":"2019","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.bcp.2024.116397_b0075","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3892\/ol.2020.11757","article-title":"Interferon-\u03b3 induced PD-L1 expression and soluble PD-L1 production in gastric cancer","volume":"20","author":"Imai","year":"2020","journal-title":"Oncol. Lett."},{"issue":"6","key":"10.1016\/j.bcp.2024.116397_b0080","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1158\/2326-6066.CIR-16-0329","article-title":"Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade","volume":"5","author":"Zhou","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"JUN","key":"10.1016\/j.bcp.2024.116397_b0085","first-page":"1","article-title":"Differential expression of immune checkpoint modulators on in vitro primed CD4+ and CD8+ T cells","volume":"7","author":"Sabins","year":"2016","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2024.116397_b0090","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10555-011-9281-4","article-title":"Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy","volume":"30","author":"Tartour","year":"2011","journal-title":"Cancer Metastasis Rev."},{"issue":"6","key":"10.1016\/j.bcp.2024.116397_b0095","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/leu.2011.24","article-title":"Immunomodulatory effects of anti-angiogenic drugs","volume":"25","author":"Heine","year":"2011","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.bcp.2024.116397_b0100","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11912-021-01140-9","article-title":"Combination therapy in renal cell carcinoma: the best choice for every patient?","volume":"23","author":"Rossi","year":"2021","journal-title":"Curr. Oncol. Rep."},{"issue":"6","key":"10.1016\/j.bcp.2024.116397_b0105","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1158\/2326-6066.CIR-17-0594","article-title":"TK inhibitor pazopanib primes DCs by downregulation of the \u03b2-catenin pathway","volume":"6","author":"Zizzari","year":"2018","journal-title":"Cancer Immunol. Res."},{"issue":"20","key":"10.1016\/j.bcp.2024.116397_b0110","doi-asserted-by":"crossref","first-page":"6674","DOI":"10.1158\/1078-0432.CCR-07-5212","article-title":"Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients","volume":"14","author":"Finke","year":"2008","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2024.116397_b0115","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-08-1332","article-title":"Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients","volume":"15","author":"Ko","year":"2009","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"issue":"22","key":"10.1016\/j.bcp.2024.116397_b0120","doi-asserted-by":"crossref","first-page":"5461","DOI":"10.1158\/1078-0432.CCR-15-2839","article-title":"Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma","volume":"22","author":"Choueiri","year":"2016","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"issue":"18","key":"10.1016\/j.bcp.2024.116397_b0125","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-13-0491","article-title":"The role of aberrant VHL\/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma","volume":"19","author":"Choueiri","year":"2013","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.bcp.2024.116397_b0130","doi-asserted-by":"crossref","DOI":"10.1038\/s41581-020-0316-3","article-title":"The immunology of renal cell carcinoma","author":"D\u00edaz-Montero","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"issue":"4","key":"10.1016\/j.bcp.2024.116397_b0135","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040667","article-title":"Soluble PD-L1 is an independent prognostic factor in clear cell renal cell carcinoma","volume":"13","author":"Larrinaga","year":"2021","journal-title":"Cancers (Basel)."},{"issue":"1","key":"10.1016\/j.bcp.2024.116397_b0140","doi-asserted-by":"crossref","first-page":"1846901","DOI":"10.1080\/2162402X.2020.1846901","article-title":"Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma","volume":"9","author":"Montemagno","year":"2020","journal-title":"Oncoimmunology"},{"issue":"23","key":"10.1016\/j.bcp.2024.116397_b0145","doi-asserted-by":"crossref","first-page":"7337","DOI":"10.1158\/1078-0432.CCR-11-1667","article-title":"Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance","volume":"17","author":"Gotink","year":"2011","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"issue":"11","key":"10.1016\/j.bcp.2024.116397_b0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206223","article-title":"Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments","volume":"13","author":"Yu","year":"2018","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.bcp.2024.116397_b0155","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00262-015-1735-z","article-title":"Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma","volume":"64","author":"Guislain","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bcp.2024.116397_b0160","first-page":"1427","article-title":"Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression","volume":"2","author":"Seliger","year":"1996","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2024.116397_b0165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer immune evasion through loss of MHC class I antigen presentation","volume":"12","author":"Dhatchinamoorthy","year":"2021","journal-title":"Front. Immunol."},{"issue":"20","key":"10.1016\/j.bcp.2024.116397_b0170","first-page":"5789","article-title":"Loss of interferon-gamma inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line","volume":"60","author":"Dovhey","year":"2000","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.bcp.2024.116397_b0175","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2024.116397_b0180","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1186\/s12885-019-5704-3","article-title":"Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis","volume":"19","author":"Deng","year":"2019","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.bcp.2024.116397_b0185","article-title":"Sunitinib or pazopanib: is there any difference between tyrosine kinase inhibitors in the pre-nivolumab setting in metastatic renal cell carcinoma?","volume":"12","author":"Ucar","year":"2020","journal-title":"Cureus"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224003800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224003800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:12:04Z","timestamp":1728346324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295224003800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":37,"alternative-id":["S0006295224003800"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116397","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116397","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116397"}}